loading
Immix Biopharma Inc stock is traded at $1.80, with a volume of 168.78K. It is up +0.55% in the last 24 hours and up +14.37% over the past month. Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.
See More
Previous Close:
$1.82
Open:
$1.8
24h Volume:
168.78K
Relative Volume:
1.49
Market Cap:
$50.89M
Revenue:
-
Net Income/Loss:
$-14.14M
P/E Ratio:
-2.25
EPS:
-0.8
Net Cash Flow:
$-12.64M
1W Performance:
+12.96%
1M Performance:
+14.37%
6M Performance:
-20.43%
1Y Performance:
-56.32%
1-Day Range:
Value
$1.71
$1.89
1-Week Range:
Value
$1.5429
$1.93
52-Week Range:
Value
$1.26
$7.75

Immix Biopharma Inc Stock (IMMX) Company Profile

Name
Name
Immix Biopharma Inc
Name
Phone
(888) 958-1084
Name
Address
11400 WEST OLYMPIC BLVD., LOS ANGELES
Name
Employee
17
Name
Twitter
Name
Next Earnings Date
2024-12-09
Name
Latest SEC Filings
Name
IMMX's Discussions on Twitter

Compare IMMX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IMMX 1.80 50.89M 0 -14.14M -12.64M -0.80
VRTX 446.83 115.43B 10.63B -479.80M -1.35B 13.33
REGN 744.22 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 592.15 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 249.71 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 104.52 24.89B 3.30B -501.07M 1.03B 11.54

Immix Biopharma Inc Stock (IMMX) Latest News

pulisher
Nov 10, 2024

Private Advisor Group LLC Has $51,000 Stake in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Nov 10, 2024
pulisher
Oct 12, 2024

Renaissance Technologies LLC Decreases Stock Holdings in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Oct 12, 2024
pulisher
Oct 06, 2024

Immix and Nexcella Make Progress in US Trial for Light Chain Amyloidosis CAR-T NXC-201 - CGTLive™

Oct 06, 2024
pulisher
Oct 04, 2024

Immix BiopharmaUS CAR-T trial progresses to dose expansion - Smartkarma

Oct 04, 2024
pulisher
Oct 03, 2024

H.C. Wainwright confident in Immix stock growth with progress in NEXICART-2 CAR-T trial - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

Immix Biopharma’s (IMMX) “Buy” Rating Reiterated at HC Wainwright - Defense World

Oct 03, 2024
pulisher
Oct 03, 2024

XTX Topco Ltd Sells 34,534 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World

Oct 03, 2024
pulisher
Oct 02, 2024

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort - GlobeNewswire

Oct 02, 2024
pulisher
Oct 02, 2024

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2 - StockTitan

Oct 02, 2024
pulisher
Oct 01, 2024

Immix Biopharma stock hits 52-week low at $1.51 amid market challenges - Investing.com Australia

Oct 01, 2024
pulisher
Sep 23, 2024

Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down - MSN

Sep 23, 2024
pulisher
Sep 21, 2024

Immix Biopharma stock hits 52-week low at $1.74 amid market challenges - Investing.com Australia

Sep 21, 2024
pulisher
Sep 19, 2024

Immix Biopharma Announces Dr. Raymond Comenzo, - GlobeNewswire

Sep 19, 2024
pulisher
Sep 19, 2024

Immix Biopharma gains AL Amyloidosis expert for advisory board - Investing.com

Sep 19, 2024
pulisher
Sep 19, 2024

Immix Biopharma gains AL Amyloidosis expert for advisory board By Investing.com - Investing.com Australia

Sep 19, 2024
pulisher
Sep 19, 2024

Immix Biopharma Announces Dr. Raymond Comenzo, Internationally Recognized AL Amyloidosis Expert, Director of the Myeloma and Amyloid Program at Tufts Medical Center, Joins Scientific Advisory Board - StockTitan

Sep 19, 2024
pulisher
Sep 14, 2024

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Update - MarketBeat

Sep 14, 2024
pulisher
Sep 02, 2024

It would be worthwhile to take a closer look at Immix Biopharma Inc (IMMX) - US Post News

Sep 02, 2024
pulisher
Sep 02, 2024

Its Stock Has Paid Off Big Time For Immix Biopharma Inc - SETE News

Sep 02, 2024
pulisher
Sep 02, 2024

The Attractiveness of Investing In Immix Biopharma Inc (IMMX) is Growing - Knox Daily

Sep 02, 2024
pulisher
Aug 29, 2024

Immix Biopharma Independent Director Acquires 2.6% More Stock - Yahoo Finance UK

Aug 29, 2024
pulisher
Aug 29, 2024

Insider Spends US$52k Buying More Shares In Immix Biopharma - Simply Wall St

Aug 29, 2024
pulisher
Aug 28, 2024

Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy - Investing.com

Aug 28, 2024
pulisher
Aug 28, 2024

Immix Biopharma expands clinical trial sites for AL Amyloidosis therapy By Investing.com - Investing.com Canada

Aug 28, 2024
pulisher
Aug 28, 2024

Immix Biopharma Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2 - GlobeNewswire

Aug 28, 2024
pulisher
Aug 28, 2024

The markets will rise or fall with NVDA - RagingBull

Aug 28, 2024
pulisher
Aug 26, 2024

Immix Biopharma director Jason Hsu buys $51,623 in company stock - Investing.com

Aug 26, 2024
pulisher
Aug 22, 2024

Best Biotech Stocks Right Now • Updated Daily - Benzinga

Aug 22, 2024
pulisher
Aug 21, 2024

Immix Biopharma Inc’s latest rating changes from various analysts - Knox Daily

Aug 21, 2024
pulisher
Aug 21, 2024

Q3 2024 Earnings Estimate for Immix Biopharma, Inc. Issued By HC Wainwright (NASDAQ:IMMX) - MarketBeat

Aug 21, 2024
pulisher
Aug 21, 2024

HC Wainwright Weighs in on Immix Biopharma, Inc.’s Q3 2024 Earnings (NASDAQ:IMMX) - Defense World

Aug 21, 2024
pulisher
Aug 20, 2024

Immix Biopharma, Inc. (NASDAQ:IMMX) Director Carey Ng Purchases 10,000 Shares of Stock - Defense World

Aug 20, 2024
pulisher
Aug 19, 2024

Immix Biopharma, Inc. (NASDAQ:IMMX) Director Purchases $18,600.00 in Stock - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

Immix Biopharma, Inc. to Post FY2024 Earnings of ($0.61) Per Share, Edison Inv. Res Forecasts (NASDAQ:IMMX) - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

Immix Biopharma, Inc. (NASDAQ:IMMX) Short Interest Down 7.5% in July - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

What Makes Immix Biopharma (IMMX) a New Buy Stock - MSN

Aug 19, 2024
pulisher
Aug 19, 2024

Immix Biopharma (NASDAQ:IMMX) Rating Reiterated by HC Wainwright - MarketBeat

Aug 19, 2024
pulisher
Aug 19, 2024

HC Wainwright Reaffirms Buy Rating for Immix Biopharma (NASDAQ:IMMX) - Defense World

Aug 19, 2024
pulisher
Aug 19, 2024

FY2024 Earnings Forecast for Immix Biopharma, Inc. (NASDAQ:IMMX) Issued By Edison Inv. Res - Defense World

Aug 19, 2024
pulisher
Aug 12, 2024

IMMX Stock Earnings: Immix Biopharma Beats EPS for Q2 2024 - InvestorPlace

Aug 12, 2024
pulisher
Aug 12, 2024

Immix Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com

Aug 12, 2024
pulisher
Aug 12, 2024

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely? - Simply Wall St

Aug 12, 2024
pulisher
Aug 05, 2024

Monitoring Immix Biopharma Inc (IMMX) after recent insider movements - Knox Daily

Aug 05, 2024
pulisher
Aug 02, 2024

Jason Hsu Purchases 6,000 Shares of Immix Biopharma, Inc. (NASDAQ:IMMX) Stock - Defense World

Aug 02, 2024
pulisher
Aug 01, 2024

Umoja Biopharma's In Situ CAR-T Therapy Cleared for US Trial in Hematologic Malignancies - CGTLive™

Aug 01, 2024
pulisher
Jul 31, 2024

Immix Biopharma director Jason Hsu buys $19.5k in company shares - Investing.com

Jul 31, 2024

Immix Biopharma Inc Stock (IMMX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immix Biopharma Inc Stock (IMMX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Hsu Jason
Director
Aug 22 '24
Buy
2.25
8,100
18,233
845,300
Ng Carey
Director
Aug 16 '24
Buy
1.86
10,000
18,600
20,000
Hsu Jason
Director
Jul 24 '24
Buy
2.15
6,000
12,877
822,200
Hsu Jason
Director
Jul 18 '24
Buy
2.07
3,200
6,639
816,200
Rachman Ilya M
CEO and Chairman
Jun 07 '24
Buy
2.13
2,600
5,538
1,136,259
Morris Gabriel S
CFO
Jun 07 '24
Buy
2.12
2,500
5,298
285,834
Morris Gabriel S
CFO
Jun 04 '24
Buy
1.81
3,300
5,973
283,334
Rachman Ilya M
CEO and Chairman
Jun 04 '24
Buy
1.81
3,300
5,970
1,133,659
Morris Gabriel S
CFO
May 14 '24
Buy
2.23
4,500
10,042
85,816
Rachman Ilya M
CEO and Chairman
May 14 '24
Buy
2.25
4,300
9,660
912,000
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):